Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Canada
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. 5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one
2. Arcapta Neohaler
3. Indacaterol
4. Onbrez
5. Qab-149
1. 753498-25-8
2. Arcapta Neohaler
3. Indacaterol (maleate)
4. Indacterol Maleate
5. Indacaterol Maleate [usan]
6. Qab149-afa
7. Qab-149-afa
8. Indacaterol (as Maleate)
9. 2jec1itx7r
10. Chebi:68573
11. 753498-25-8 (malate)
12. Qabi49
13. (r)-5-(2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one Maleate
14. Qab-149 Maleate
15. Unii-2jec1itx7r
16. Qab 149afa
17. Oslif Breezhaler
18. Onbrez Breezhaler
19. Hirobriz Breezhaler
20. (r)-5-[2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one Maleate
21. Arcapta Neohaler (tn)
22. Onbrez Inhalation Capsules
23. Indacaterol Maleic Acid Salt
24. Schembl523627
25. Chembl1789842
26. Indacaterol Maleate [mi]
27. Indacaterol Maleate (jan/usan)
28. Indacaterol Maleate [jan]
29. Hms3885o07
30. Indacaterol Maleate [mart.]
31. Hy-14299a
32. Indacaterol Maleate [who-dd]
33. Mfcd20526769
34. Indacaterol Maleate [ema Epar]
35. Ccg-269764
36. Indacaterol Maleate [orange Book]
37. Ac-30121
38. As-10152
39. Ultibro Component Indacaterol Maleate
40. I0927
41. Qva149 Component Indacaterol Maleate
42. S3083
43. Qva-149 Component Indacaterol Maleate
44. D09319
45. Indacaterol Maleate Component Of Utibron
46. Q27137018
47. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h- Pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Dihydrogen Phosphate
48. (z)-but-2-enedioic Acid;5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one
49. 2(1h)-quinolinone, 5-((1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl )-8-hydroxy-, (2z)-2-butenedioate (1:1)
50. 2(1h)-quinolinone, 5-((1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxy-, (2z)-2-butenedioate (1:1)
51. 435273-74-8
52. 5,6-diethyl-n-[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]indan-2-aminium (2z)-3-carboxyacrylate
53. 5-((1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl)-8- Hydroxyquinolin-2(1h)-one Hydrogen (2z)-2-butenedioate (salt)
54. 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one Maleate
55. 5-{(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1h)-one (2z)-but-2-enedioate
Molecular Weight | 508.6 g/mol |
---|---|
Molecular Formula | C28H32N2O7 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 8 |
Exact Mass | 508.22095136 g/mol |
Monoisotopic Mass | 508.22095136 g/mol |
Topological Polar Surface Area | 156 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 708 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Arcapta neohaler |
PubMed Health | Indacaterol (By breathing) |
Drug Classes | Bronchodilator |
Drug Label | ARCAPTA NEOHALER consists of a dry powder formulation of indacaterol maleate for oral inhalation only with the NEOHALERinhaler. The inhalation powder is packaged in clear gelatin capsules.Each clear, hard gelatin capsule contains a dry powder blend... |
Active Ingredient | Indacaterol maleate |
Dosage Form | Powder |
Route | Inhalation |
Strength | eq 75mcg base |
Market Status | Prescription |
Company | Novartis |
2 of 2 | |
---|---|
Drug Name | Arcapta neohaler |
PubMed Health | Indacaterol (By breathing) |
Drug Classes | Bronchodilator |
Drug Label | ARCAPTA NEOHALER consists of a dry powder formulation of indacaterol maleate for oral inhalation only with the NEOHALERinhaler. The inhalation powder is packaged in clear gelatin capsules.Each clear, hard gelatin capsule contains a dry powder blend... |
Active Ingredient | Indacaterol maleate |
Dosage Form | Powder |
Route | Inhalation |
Strength | eq 75mcg base |
Market Status | Prescription |
Company | Novartis |
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease
R03AC18
R03AC18
R03AC18
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 623
2019 Revenue in Millions : 630
Growth (%) : -1
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 479
2021 Revenue in Millions : 584
Growth (%) : -18
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : 14.60%
2013 Revenue in Millions :
Growth (%) :
Indacaterol / Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : 1866.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 220
2014 Revenue in Millions : 166
Growth (%) : -25%
Indacaterol And Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 363
2015 Revenue in Millions : 260
Growth (%) : 40
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 143
2015 Revenue in Millions : 166
Growth (%) : -14
Indacaterol and Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 411
2016 Revenue in Millions : 363
Growth (%) : 13
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 112
2016 Revenue in Millions : 143
Growth (%) : -22
Indacaterol And Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 454
2017 Revenue in Millions : 411
Growth (%) : 10%
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?